DORATrial

Updates on the Phase III Trial of Docetaxel versus Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (NCT03574571)

[DORATrial @DoraTrial]

Brazil's Hospital de Amor de Barretos (Fundação Pio XII) is now enrolling patients onto @DoraTrial: A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer (NCT03574571) https://t.co/uDarUcfS3B

[DORATrial @DoraTrial]

We are excited to announce Clinic de Barcelona 🇪🇸 and Instituto de Medicina Integral Professor Fernando Figueira (IMIP) 🇧🇷 have activated our phase 3 study to test radium-223 with docetaxel in patients with prostate cancer: https://t.co/uDarUcfS3B

[DORATrial @DoraTrial]

¡Felicidades! Hospital Universitario Central de Asturias (HUCA) 🇪🇸 has randomized its first participant to DORA: A Phase 3 Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer https://t.co/uDarUcgpT9

[DORATrial @DoraTrial]

Maasstad Ziekenhuis (🇳🇱) has enrolled its 200th participant to DORA! To learn more about this Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC) visit https://t.co/uDarUcfS3B

[DORATrial @DoraTrial]

We are pleased to announce Instituto Brasileiro de Controle do Câncer (São Paulo) enrolled the first Brazilian participant to DORA: A Phase 3 Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer https://t.co/uDarUcfS3B

[DORATrial @DoraTrial]

Marking an important milestone, @DoraTrial, A phase 3 study to test radium-223 with docetaxel (NCT03574571), randomized its 500th patient with prostate cancer today! https://t.co/uDarUcfS3B

[DORATrial @DoraTrial]

🇪🇸 Three Spanish sites—Ramón y Cajal Hospital, Hospital Del Mar, Instituto Valenciano de Oncología—are now enrolling patients with advanced prostate cancer to DORA, the phase 3 study testing radium-223 with docetaxel 🇪🇸 More info: https://t.co/uDarUcfS3B

[DORATrial @DoraTrial]

🇪🇸 Spain is the latest country to participate in @DoraTrial: A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer, with the addition of Barcelona's Hospital Del Mar 🇪🇸 https://t.co/QNp0EtBTOG

[DORATrial @DoraTrial]

🇳🇱 We are excited to announce The Netherlands Cancer Institute (@NKI_nl) is now participating in our phase 3 study testing radium-223 with docetaxel in patients with #prostatecancer, under the local leadership of Dr Andre Bergman! For more info visit https://t.co/QNp0EtBTOG

[DORATrial @DoraTrial]

A strong commitment between investigators, research professionals, patients, and advocates advances our search for improved standards of care.

[The PCCTC @ThePCCTC]

The PCCTC-managed @DoraTrial (NCT03574571), a phase 3 study to test radium-223 with docetaxel in patients with #prostatecancer, is now 60% accrued. To learn more about this important trial for advanced disease visit https://t.co/SA1QDcnj7A

[DORATrial @DoraTrial]

The Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant #ProstateCancer (DORA) is now enrolling at 53 sites in the US and Netherlands. For more info visit https://t.co/NfuyhebZZ1

[The PCCTC @ThePCCTC]

@DoraTrial principal investigator Dr @morr316 discusses the aims, rationale and implications of the phase 3 prostate cancer study (NCT03574571): https://t.co/X9WOs1n4TY

[The PCCTC @ThePCCTC]

The PCCTC's phase 3 DORA trial (NCT03574571) of radium-223 with docetaxel in patients with #ProstateCancer

[DORATrial @DoraTrial]

DORA, The phase 3 #clinicaltrial of docetaxel vs. docetaxel and radium-223 for metastatic castration-resistant #prostatecancer is now enrolling at 53 sites in the US and Netherlands. For more info visit https://t.co/TrPgUABYsn

[DORATrial @DoraTrial]

From Stichting Dutch Uro-Oncology Studygroup (DUOS), "Investigators Meeting DORA met @morr316" 🇳🇱: https://t.co/Mnonj7dN48

[DORATrial @DoraTrial]

With the dedicated work of our Dutch research staff, clinicians, advocates, and patients we continue to make progress on this important #prostatecancer clinical trial.

[The PCCTC @ThePCCTC]

Members of our @DoraTrial operations team recently visited the 🇳🇱 to meet with the Dutch site staff and investigators. Thanks to all for a wonderful and engaging meeting. Looking forward to our continued collaboration!

[DORATrial @DoraTrial]

400 patients with #prostatecancer have now been randomized to the @DoraTrial. To learn more about this phase 3 study testing Radium-223 with docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) visit: https://t.co/NfuyhecxOz

[KMittaloncMD @KMittalmd]

Congratulations to the DORA team @ThePCCTC and @morr316 for reaching this milestone. Study open to accrual at @UMassCancerCtr !

[DORATrial @DoraTrial]

A message from Dr @morr316, @DoraTrial PI, on reaching the important milestone of 50% accrual: https://t.co/9QboIjARrt

[Charles Ryan @charlesryanmd]

Great Article about @morr316 @SocietyofMSKCC - One of the most thoughtful researchers and clinicians in the field. There is more to come from this team! Triumph Against Prostate Cancer https://t.co/WTFCj89tES